132 related articles for article (PubMed ID: 9949905)
21. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
22. Tumor-infiltrating lymphocytes expressing IOT-10 marker. An immunohistochemical study of a series of 185 brain tumors.
Zurita M; Vaquero J; Coca S; Oya S; Garcia N
Histol Histopathol; 1993 Apr; 8(2):345-50. PubMed ID: 8490262
[TBL] [Abstract][Full Text] [Related]
23. Comparative analysis of alternative and traditional immunohistochemical markers for the distinction of ovarian sertoli cell tumor from endometrioid tumors and carcinoid tumor: A study of 160 cases.
Zhao C; Bratthauer GL; Barner R; Vang R
Am J Surg Pathol; 2007 Feb; 31(2):255-66. PubMed ID: 17255771
[TBL] [Abstract][Full Text] [Related]
24. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
25. Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma.
Fan YS; Carr RA; Sanders DS; Smith AP; Lazar AJ; Calonje E
Histopathology; 2007 Jul; 51(1):80-6. PubMed ID: 17593083
[TBL] [Abstract][Full Text] [Related]
26. Application of immunohistochemistry in the differential diagnosis of skin tumors.
Googe PB; Bhan AK; Mihm MC
Clin Lab Med; 1990 Mar; 10(1):179-97. PubMed ID: 2184977
[TBL] [Abstract][Full Text] [Related]
27. [The role of epithelial antigens in diagnosis and staging of breast cancer].
Artamonova EV; Tupitsyn NN; Kadagidze ZG; Letiagin VP; Ermilova VD; Ognerubov NA; Panichenko AV; Riazantseva SN
Arkh Patol; 2002; 64(6):13-5. PubMed ID: 12534220
[TBL] [Abstract][Full Text] [Related]
28. [Changes of microenvironment and tumor cell heterogeneity--consequences for bioptic diagnosis].
Gottschalk J; Jautzke G; Zimmer C
Acta Histochem Suppl; 1992; 42():149-54. PubMed ID: 1374917
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear-cell renal cell carcinoma in the brain: utility of aquaporin1 combined with cytokeratin AE1/AE3 immunostaining.
Weinbreck N; Marie B; Bressenot A; Montagne K; Joud A; Baumann C; Klein O; Vignaud JM
Am J Surg Pathol; 2008 Jul; 32(7):1051-9. PubMed ID: 18496143
[TBL] [Abstract][Full Text] [Related]
30. Value and limits of immunohistochemistry in differential diagnosis of clear cell primary brain tumors.
Koperek O; Gelpi E; Birner P; Haberler C; Budka H; Hainfellner JA
Acta Neuropathol; 2004 Jul; 108(1):24-30. PubMed ID: 15108012
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies: their application in the diagnosis and management of CNS tumors.
de Tribolet N; Frank E; Mach JP
Clin Neurosurg; 1988; 34():446-56. PubMed ID: 3288406
[No Abstract] [Full Text] [Related]
32. [HEA125 and BerEP4 in neuro-oncologic differential diagnosis].
Gottschalk J; Jautzke G; Zimmer C; Paulus W; Cervos-Navarro J
Pathologe; 1992 Apr; 13(2):95-9. PubMed ID: 1603778
[No Abstract] [Full Text] [Related]
33. Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms.
Yu H; Pinkus GS; Hornick JL
Am J Clin Pathol; 2007 Nov; 128(5):767-75. PubMed ID: 17951198
[TBL] [Abstract][Full Text] [Related]
34. Intracranial malignancy in patients with bilateral retinoblastoma.
Donoso LA; Shields JA; Felberg NT; Martyn LJ; Truex RC; D'Cruz CA
Retina; 1981; 1(1):67-74. PubMed ID: 15633409
[TBL] [Abstract][Full Text] [Related]
35. [Cell-block immunocytochemical characterization of effusions. Use of antibody panel: calretinin, Ber-EP4, keratin and CD68].
Lucchi I; Morigi F; Naldi S; Tabarri B; Elegibili E; Giangaspero F
Pathologica; 1999 Dec; 91(6):447-52. PubMed ID: 10783640
[TBL] [Abstract][Full Text] [Related]
36. [Immunomorphological study of human tumors using the monoclonal antibody RMZh-1].
Kulevich EE; Sedel'nikova OA; Petrovichev NN; Chistiakova OV
Arkh Patol; 1993; 55(2):6-8. PubMed ID: 7526832
[TBL] [Abstract][Full Text] [Related]
37. Assessment of tumor markers in cerebrospinal fluid.
Jaeckle KA
Clin Lab Med; 1985 Jun; 5(2):303-15. PubMed ID: 2411459
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update.
Baker PM; Oliva E
Int J Gynecol Pathol; 2005 Jan; 24(1):39-55. PubMed ID: 15626916
[TBL] [Abstract][Full Text] [Related]
39. Detection of disseminated lung cancer cells in lymph nodes by monoclonal antibodies: impact on staging and prognosis.
Passlick B
Ann Ital Chir; 1999; 70(6):839-40. PubMed ID: 10804658
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.
Scartozzi M; Bearzi I; Berardi R; Mandolesi A; Fabris G; Cascinu S
J Clin Oncol; 2004 Dec; 22(23):4772-8. PubMed ID: 15570078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
